| Literature DB >> 24236088 |
Brendon P Scicluna1, Cornelis van 't Veer, Max Nieuwdorp, Karen Felsmann, Britta Wlotzka, Erik S G Stroes, Tom van der Poll.
Abstract
TNFα has been implicated in the pathogenesis of various inflammatory diseases. Different strategies to inhibit TNFα in patients with sepsis and chronic inflammatory conditions have shown contrasting outcomes. Although TNFα inhibitors are widely used in clinical practice, the impact of TNFα antagonism on white blood cell gene expression profiles during acute inflammation in humans in vivo has not been assessed. We here leveraged the established model of human endotoxemia to examine the effect of the TNFα antagonist, etanercept, on the genome-wide transcriptional responses in circulating leukocytes induced by intravenous LPS administration in male subjects. Etanercept pre-treatment resulted in a markedly dampened transcriptional response to LPS. Gene co-expression network analysis revealed this LPS-induced transcriptome can be categorized as TNFα responsive and non-responsive modules. Highly significant TNFα responsive modules include NF-kB signaling, antiviral responses and T-cell mediated responses. Within these TNFα responsive modules we delineate fundamental genes involved in epigenetic modifications, transcriptional initiation and elongation. Thus, we provide comprehensive information about molecular pathways that might be targeted by therapeutic interventions that seek to inhibit TNFα activity during human inflammatory diseases.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24236088 PMCID: PMC3827317 DOI: 10.1371/journal.pone.0079051
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
White blood cell counts and differentials before and 4 hours after intravenous endotoxin administration in healthy subjects pretreated with etanercept or placebo.
| Baseline (t = 0) | Post Endotoxin (t = 4 hours) | |||
|
|
|
|
| |
| Cell Type | Mean ±SEM (n = 8) | Mean ±SEM (n = 8) | Mean ±SEM (n = 8) | Mean ±SEM (n = 8) |
| WBC (×109/L) | 5.00±0.19 | 5.35±0.63 | 9.80±0.74 | 10.64±0.98 |
| Neutrophils (%) | 54.31±1.73 | 52.26±3.08 | 87.01±5.04 | 82.83±1.66 |
| Eosinophils (%) | 2.72±0.14 | 2.88±0.44 | 8.73±0.94 | 8.73±0.72 |
| Basophils (%) | 1.86±0.19 | 3.31±0.93 | 0.36±0.16 | 1.51±0.67 |
| Lymphocytes (%) | 34.44±1.76 | 36.66±3.17 | 9.39±3.96 | 11.68±0.66 |
| Monocytes (%) | 8.96±0.48 | 7.26±0.8 | 1.94±0.39 | 3.69±0.77 |
Sixteen healthy males received an intravenous injection with endotoxin (1 ng/kg) at t = 0. Subjects were pretreated (−48 hours) with etanercept (50 mg, n = 8) or placebo (n = 8). White blood cell counts (WBC) and differentials were determined directly before and 4 hours after endotoxin injection.
***p<0.001; paired student t test of placebo-treated baseline and endotoxin infusion groups.
p<0.01,
p<0.001; paired student t test of etanercept-treated baseline and endotoxin infusion groups. There were no differences between etanercept and placebo treated subjects at either t = 0 or t = 4 hours.
Figure 1Genomic analysis of the systemic LPS-induced transcriptional response and impact of TNFα inhibition.
A. Volcano plot analysis (integrating p-values and log2 foldchanges) for the LPS-induced response in subjects treated with placebo. B. Volcano plot analysis of the LPS-induced response in subjects treated with the TNFα antagonist etanercept. Red dots in panels A and B indicate probes that showed a fold-change ≥1.5 or ≤1.5. C. Unsupervised hierarchical clustering heatmap of the 4077 LPS-induced transcripts that were influenced by etanercept treatment as identified by ANOVA (q-value <0.05). Columns represent subject samples and rows represent transcripts. Red indicates increased gene expression, and blue indicates decreased gene expression.
Functional annotation and hub genes for the LPS-induced co-expression modules.
| Canonical pathway | Module size | p-value | Hub gene | Hub gene functional signature |
| NF-kB signaling | 829 | 3.4×10−8 |
| transcription factor activity |
| Role of PKR in Interferon Induction and Antiviral Response | 578 | 8.8×10−8 |
| chromatin modification |
| T Cell Receptor Signaling | 131 | 0.015 |
| lipid binding |
| Ceramide signaling | 221 | 7.0×10−5 |
| RNA binding |
| Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes | 218 | 0.001 |
| receptor activity |
| Alanine Biosynthesis III | 68 | 0.003 |
| receptor activity |
| TWEAK Signaling | 61 | 3.4×10−4 |
| endopeptidase activity |
| Pyrimidine Ribonucleotides Interconversion | 44 | 0.055 |
| RNA polymerase activity |
| Hypoxia Signaling in the Cardiovascular System | 89 | 0.011 |
| unknown |
| Caveolar-mediated endocytosis signaling | 216 | 0.008 |
| unknown |
| Ephrin Receptor Signaling | 247 | 1.6×10−4 |
| kinase activity |
| GNRH signaling | 63 | 4.2×10−4 |
| heat shock protein binding |
| Interferon signaling | 97 | 1.7×10−5 |
| DNA binding |
| Retinoate Biosynthesis I | 99 | 0.006 |
| translation initiation activity |
| IL-10 Signaling | 205 | 0.002 |
| DNA binding |
| EIF2 signaling | 243 | 2.4×10−24 |
| unknown |
| NRF2-mediated Oxidative Stress Response | 195 | 0.012 |
| nucleotide binding |
| Fatty Acid b-oxidation I | 48 | 0.002 |
| lipid binding |
| Calcium Signaling | 64 | 0.003 |
| cell adhesion |
| IL-4 Signaling | 53 | 9.8×10−4 |
| unknown |
| Methionine Salvage II (Mammalian) | 60 | 0.012 |
| chromatin modification |
| Mismatch Repair in Eukaryotes | 131 | 2.0×10−4 |
| endopeptidase activity |
| Cell Cycle Control of Chromosomal Replication | 127 | 0.016 |
| RNA polymerase activity |
| LPS/IL-1 Mediated Inhibition of RXR Function | 60 | 8.7×10−4 |
| nucleotide binding |
| CTLA4 Signaling in Cytotoxic T Lymphocytes | 100 | 0.001 |
| unknown |
| Natural Killer Cell Signaling | 54 | 5.1×10−8 |
| phosphotyrosine binding |
| Assembly of RNA Polymerase II Complex | 213 | 0.003 |
| translation repressor |
| b-alanine Degradation I | 33 | 0.004 |
| cholinesterase activity |
| B Cell Development | 72 | 5.8×10−8 |
| receptor activity |
| Dolichol and Dolichyl Phosphate Biosynthesis | 225 | 1.8×10−4 |
| oxidoreductase activity |
| fMLP Signaling in Neutrophils | 49 | 0.006 |
| zinc ion binding |
| g-glutamyl Cycle | 206 | 0.008 |
| RNA binding |
| Protein Ubiquitination Pathway | 137 | 0.008 |
| RNA binding |
| Mitochondrial Dysfunction | 143 | 9.3×10−5 |
| aldehyde reductase activity |
| Purine Nucleotides De Novo Biosynthesis II | 211 | 2.5×10−4 |
| transaminase activity |
| Acute Phase Response Signaling | 79 | 0.006 |
| transcription factor activity |
| Leukocyte Extravasation Signaling | 170 | 0.003 |
| unfolded protein binding |
| 4-aminobutyrate Degradation I | 99 | 0.017 |
| kinase activity |
LPS-induced transcriptome is organized into 38 co-expression network modules. Each module was analyzed for enrichment of biological pathways by IPA (Ingenuity® systems, www.ingenuity.com).
Figure 2LPS-induced TNFα responsive and non-responsive transcriptional module delineation by weighted correlation analysis.
Each transcriptional module, encompassing highly intercorrelating transcripts, was represented by its first principal component across all samples (module eigengene). A. Bar plot of module significance for the effect of etanercept on the LPS-response based on unpaired student t statistics of the module eigengene between post-LPS samples from placebo and etanercept-treated subjects. The red line denotes the multiple-test corrected significance threshold (−log10 p = 2.88). B. Bar plot denoting the upregulated and downregulated gene counts per IPA (ww.ingenuity.com) interactome pathway for both the LPS-challenged placebo-treated and LPS-challenged etanercept-treated samples.
LPS-induced TNFα responsive module genes linked to transcriptional initiation, elongation and epigenetic regulation.
|
| |||||||
| Functional group | Gene name | Module | kTotal | kWithin | kOut |
|
|
| DNA/RNA methylation |
| Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes | 45.43 | 13.52 | 31.9 | −1.7 | −0.9 |
|
| Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes | 101.61 | 15.2 | 86.41 | −1.2 | −0.5 | |
| histone deacetylation |
| IL10 signaling | 31.15 | 4.8 | 26.35 | −0.6 | −0.2 |
|
| NF-kB signaling | 33.61 | 16.23 | 17.38 | 0.6 | −0.03 | |
|
| Role of PKR in Interferon Induction and Antiviral Response | 30.08 | 8.33 | 21.76 | −0.5 | −0.1 | |
| histone acetylation |
| Ephrin Receptor Signaling | 41.06 | 8.44 | 32.61 | 0.3 | 0.09 |
| histone-lysine N-methyltransferase |
| Interferon signaling | 26.66 | 5.07 | 21.59 | −0.3 | 0.06 |
| chromobox/HP1 homologs |
| Role of PKR in Interferon Induction and Antiviral Response | 81.81 | 23.2 | 58.61 | −0.8 | 0.03 |
|
| GNRH signaling | 0.26 | 0.15 | 0.11 | 0.4 | 0.1 | |
|
| Hypoxia Signaling in the Cardiovascular System | 0.35 | 0.03 | 0.32 | −0.3 | −0.03 | |
| bromodomain |
| Interferon signaling | 55.95 | 4.79 | 51.16 | −1.2 | −0.3 |
|
| IL-10 Signaling | 1.53 | 0.38 | 1.16 | 0.4 | 0.1 | |
| Chromodomain/Helicase/DNA-Binding Domain |
| NF-kB signaling | 47.04 | 19.05 | 27.99 | 0.9 | 0.3 |
|
| Caveolar-mediated endocytosis signaling | 14.18 | 7.11 | 7.07 | 0.8 | 0.2 | |
|
| Role of PKR in Interferon Induction and Antiviral Response | 2.4 | 0.83 | 1.56 | 1.1 | 0.5 | |
| chromatin insulator binding |
| Interferon signaling | 8.05 | 2.07 | 5.98 | −0.6 | −0.2 |
Genes within LPS-induced TNFα responsive co-expression modules possessing epigenetic regulation, transcriptional initiation and elongation properties. kTotal, total connectivity, k. kWithin, intra-modular connectivity. kOut, extra-modular connectivity. log2 FC LPS, log2 transformed foldchange for the placebo-treated pre- and post-LPS challenged samples. log2 FC LPS+Etan, log2 transformed foldchange for the etanercept-treated pre- and post-LPS challenged samples. Gene names marked in bold type denote module genes identified as top module hub genes.
Figure 3TNFα responsive module hub (driver) genes and co-expression network visualization.
Genes within transcriptional modules can be categorized as peripheral or hubs on the basis of how correlated a gene is with all other genes in the network, defined as the genes' connectivity measure, k. High intramodulr connectivities denote highly important module genes oftentimes possessing transcriptional factor activity. A. Unsupervised hierarchical clustering heatmap plot of the TNFα responsive module hub genes. Red denotes high expression; blue denotes low expression. The relative importance of each module within the co-expression network can be highlighted by unsupervised visualizations of each genes' weighted correlation coefficient. This was implemented in the Cytoscape® platform B. TNFα responsive co-expression modules were visualized by an organic layout considering weighted correlation coefficients >0.1 (equivalent to correlation coefficient >0.9).
Figure 4Interactome relationships of the core TNFα responsive co-expression modules.
Integrating IPA (www.ingenuity.com) derived experimentally observed gene functional and co-expression network relationships allowed for the construction of a LPS-induced and TNFα-responsive gene activity model anchored at important hub genes. Panel a. illustrates the interactome relationships among transcripts in the NF-kB signaling and role of PKR in interferon induction and antiviral response modules with HIVEP1 and CBX7 as hub genes, respectively. Panel b. illustrates the interactome relationships among the regulation of IL-2 expression in activated and anergic T lymphocytes module with CD6 as hub gene. Foldchanges (Red denotes high expression, green denotes low expression) derived from the differential gene expression analysis of the unpaired LPS+placebo and LPS+etanercept comparison where genes present significant ANOVA q-values (q<0.05). IPA interactome inference denoted by gray edges; gene coexpression network relationships denoted by turquoise (NF-kB signaling), purple (IL10 signaling), red (Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes), yellow (Ephrin Receptor Signaling) and blue (Role of PKR in Interferon Induction and Antiviral Response) edges.